Results 41 to 50 of about 381 (103)

1282. Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In vitro Activity Against Members of the Fusarium oxysporum and Fusarium solani Species Complexes [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background Invasive fusariosis is associated with marked morbidity and mortality in immunocompromised hosts, and treatment options are limited. Common etiologic agents include members of the F. oxysporum and F. solani species complexes (FOSC and FSSC, respectively).
Badali, Hamid, Patterson, Hoja, Sanders, Carmita, Mermella, Barbara, Gibas, Connie, Mele, James, Fan, Hongxin, Ibrahim, Ashraf S, Shaw, Karen J, Wiederhold, Nathan P   +9 more
openaire   +1 more source

2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type

Open Forum Infectious Diseases, 2022
Abstract Background Manogepix is a new antifungal with a novel mechanism of action and potent in vitro activity against Candida (except C. krusei), Aspergillus, and rare mold isolates. The manogepix prodrug fosmanogepix is in Phase 2 development for the treatment of invasive mold infections caused by ...
Huband, Michael D, Pfaller, Michael, Carvalhaes, Cecilia G, Bien, Paul, Castanheira, Mariana   +4 more
openaire   +1 more source

Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains. [PDF]

Antimicrob Agents Chemother
ABSTRACT This study comprehensively assessed the activity of manogepix (MNGX), ibrexafungerp (IBF), amphotericin B (AMB), rezafungin (RZF), and caspofungin (CAS) against planktonic cells and mature biofilms of Candida spp.—reference and clinical strains using the Calgary ...
Ceballos-Garzon A, Lebrat J, Holzapfel M, Josa DF, Welsch J, Mercer D.   +5 more
europepmc   +3 more sources

Molecular Insights into Fungal Glycosylphosphatidylinositol Transamidase Complex

Advanced Science, Volume 13, Issue 2, 9 January 2026.
The glycosylphosphatidylinositol (GPI) biosynthesis pathway is critical for antifungal drug development. This study reports three cryo‐electron microscopy structures of fungal GPI transamidase (GPIT), captured in two substrate‐bound states and a novel dimeric assembly.
Zhengkang Hua, Xuyang Ding, Yanan Wu, Di Zhang, Xinlin Hu, Ping Yang, Jiameng Li, Yi Tan, Junbo Liu, Mingjie Zhang, Min Zhang, Xiaotian Liu, Hongjun Yu   +12 more
wiley   +1 more source

Antifungal Resistance in Non‐fumigatus Aspergillus Species

Mycoses, Volume 68, Issue 4, April 2025.
ABSTRACT This review provides an in‐depth exploration of antifungal resistance in non‐fumigatus Aspergillus species, mainly focusing on acquired resistance. The available data have been compiled and sometimes re‐analysed. It highlights the increasing prevalence of resistance in non‐fumigatus species belonging to Flavi, Terrei, Nigri, and Nidulantes ...
Elie Djenontin, Rose‐Anne Lavergne, Florent Morio, Eric Dannaoui   +3 more
wiley   +1 more source

P-1194. Activity of manogepix against mould isolates collected from the US in 2023 [PDF]

Open Forum Infect Dis
Abstract Background Manogepix (MGX) is a novel agent targeting the fungal Gwt1 enzyme. This agent is undergoing phase 3 clinical trials for invasive candidiasis and mould infections. Here, we assessed the in vitro activity of MGX against US mould isolates from invasive infections.
Winkler, Marisa, Edeker, Samuel, Klauer, Abby, Rhomberg, Paul, Castanheira, Mariana   +4 more
europepmc   +2 more sources

<i>In vitro</i> activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022). [PDF]

Antimicrob Agents Chemother
ABSTRACT Manogepix is a potent new antifungal agent targeting the fungal Gwt1 enzyme. Manogepix has previously demonstrated potent in vitro activity against clinical isolates of both Candida (except Candida krusei ) and Aspergillus ...
Pfaller M, Huband M, Bien PA, Carvalhaes CG, Klauer A, Castanheira M.   +5 more
europepmc   +3 more sources

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

Chemical Biology &Drug Design, Volume 105, Issue 1, January 2025.
The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley   +1 more source

P-1195. Activity of manogepix against surveillance yeast isolates collected from the United States in 2023 [PDF]

Open Forum Infect Dis
Abstract Background Manogepix (MGX) targets the fungal Gwt1 enzyme. Fosmanogepix, the prodrug of MGX is undergoing phase 3 clinical trials for treating invasive candidiasis and mould infections.
Winkler, Marisa, Edeker, Samuel, Klauer, Abby, Rhomberg, Paul, Castanheira, Mariana   +4 more
europepmc   +2 more sources

Planejamento e síntese de análogos do manogepix como agentes antifúngicos

, 2022
Pós-graduação em Química ...
openaire   +1 more source